Pawin Numthavaj

1 Introduction In 2022, thyroid cancer was ranked seventh among all cancers. The age-standardized rate of thyroid cancer is 9.1, and the incidence of thyroid cancer is rising annually in all areas of the world, especially in Asia [1, 2]. In our hospital, thyroid cancer is also the seventh leading site [3], and papillary thyroid carcinoma (PTC) is the majority histopathologic subtype, accounting for about 80%–85% of all thyroid cancer [4, 5].

Methods This SR and NMA will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA Network Meta-Analysis Extension statement.35 36 Parallel or cross-over RCTs that directly compared any pairs of both oral and injectable preventive active treatments, placebo or no intervention will be eligible. Cross-over RCTs will be included if the results of the first administration are reported separately.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.